The treatment of tuberculosis: current status and future prospects

Bibliography

• GRANGE J: Vaccination against tuberculosis: past prob-lems and future hopes. Semin. Respir. Crit. Care Med. (1997) 18:459–470.
   Web of Science ®Google Scholar
• HOLME C: Trial by TB: a study into current attempts to control the international upsurge in tuberculosis. Proc. Roy Coll. Phys. Edin. (1997) 27\(Suppl. 4.):1–53.
   Google Scholar
• COLSTON J: The return of the great white plague. Biolo-gist (1997) 44:392–394.
   Google Scholar
• BAYER R, WILKINSON D: Directly observed therapy for tuberculosis: history of an idea. Lancet (1995) 345:1545–1548.
   PubMed Web of Science ®Google Scholar
• SNELL N, DAVIES P: New treatments for tuberculosis -whose responsibility? Int. J. Tuberc. Lung Dis. (1997) 1 (Suppl. 1):S50.
   Google Scholar
• AMERICAN THORACIC SOCIETY OFFICIAL STATEMENT: Treatment of tuberculosis and tuberculosis infection in adults and children. Am. J. Respir. Crit. Care Med. (1994) 149:1359–1374.
   PubMed Web of Science ®Google Scholar
• HOUSTON S, FANNING A: Current and potential treat-ment of tuberculosis. Drugs (1994) 48:689–708.
   PubMed Web of Science ®Google Scholar
• DOOLEY D, CARPENTER J, RADEMACHER S: Adjunctive corticosteroid therapy for tuberculosis: a critical reap-praisal of the literature. Clin. Infect. Dis. (1997) 25:872–887.
   PubMed Web of Science ®Google Scholar
• CALLEJA C, PASCUSSI J, MANI J, MAUREL P, VALAREM M:The antibiotic rifampicin is a nonsteroid ligand and ac-tivator of the human glucocorticoid receptor. Nature Med. (1998) 4:92–96.
   PubMed Web of Science ®Google Scholar
• DROBNIEWSKI F, POZNIAK A, UTTLEY A: Tuberculosis and AIDS. J. Med. Microbiol. (1995) 43:85–91.
   PubMed Web of Science ®Google Scholar
• NAKATA K et al: Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am. J. Respir. Crit. Care Med. (1997) 155:996–1003.
   PubMed Web of Science ®Google Scholar
• WHALEN C et al: A trial of three regimens to prevent tu-berculosis in Ugandan adults infected with the human immunodeficiency virus. New EngI J. Med. (1997) 337:801–808.
   PubMed Web of Science ®Google Scholar
• OLLIARO P et al.: Rifabutin for prevention and treat-ment of mycobacterial disease: a review of microbiol-ogy, clinical pharmacology, efficacy and tolerability data. Eur. Respir. Rev. (1995) 5(25):77–83.
   Google Scholar
• UNGHERI D, DELLA BRUNA C, SANFILIPPO A: Studies on the mechanism of action of the spiropiperydil-rifamycin LM427 on rifampicin-resistant M. tubercu-losis. Drugs Exp. Clin. Res. (1984) 10:681–689.
   Web of Science ®Google Scholar
• KANYOK T: A lesson to be learned. Int. J. Tuberc. Lung Dis. (1997) 1: 490–492.
   PubMed Web of Science ®Google Scholar
• BAKER W, MITSCHER L, ARAIN T, SHAWAR R, STOVER C:Recent advances in the chemistry and biology of an-timycobacterial agents. Ann. Rep. Med. Chem. (1996) 31 :161–170.
   Web of Science ®Google Scholar
• YEW W et al.: In vitro activity of quinolones and mac-rolides against mycobacteria. J. Antimicrob. Chemother. (1994) 34:343–351.
   PubMed Web of Science ®Google Scholar
• BERNING S, MADSEN L, ISEMAN M, PELOQUIN C: Long-term safety of ofloxacin and ciprofloxacin in the treat-ment of mycobacterial infections. Am. J. Respk. Crit. Care Med. (1995) 151:2006–2009.
   PubMed Web of Science ®Google Scholar
• KENNEDY N et al.: Randomised controlled trial of adrug regimen that includes ciprofloxacin for the treat-ment of pulmonary tuberculosis. Clin. Infect. Dis. (1996) 22:827–833.
   PubMed Web of Science ®Google Scholar
• HONG KONG CHEST SERVICE/BRITISH MEDICAL RE-SEARCH COUNCIL A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin, and rifampicin. Tuberc. Lung Dis. (1992) 73:59–67.
   PubMedGoogle Scholar
• SULLIVAN E et al.: Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet (1995) 345:1148–1150.
   PubMed Web of Science ®Google Scholar
• BANERJEE S, BHATT K, RANA S, MISRA P, CHAKRABORTIP: Involvement of an efflux system in mediating high levels of fluoroquinolone resistance in Mycobacte-rium smegmatis. Biochem. Biophys. Res. Comm. (1996) 226:362–368.
   PubMed Web of Science ®Google Scholar
• LUNA-HERRERA J, REDDY V, GANGADHARAM P: Syner-gistic effect of clarithromycin and isoniazid and ri-fampin against tubercle bacilli. In: Programs and Abstracts of the 34th ICAAC. Orlando, Florida, USA October 1994. American Society for Microbiology (1994). Abstract E 134.
   Google Scholar
• WONG C, PALMER G, GYNAMON M: In vitro susceptibil-ity of M tuberculosis, M bovis, and M kansasii to amoxycillin and ticarcillin in combination with clavu-lanic acid. J Antimicrob. Chemother. (1988) 22:863–866.
   PubMed Web of Science ®Google Scholar
• NADLER J, BERGER J, NORD J, COFSKY R, SAXENA M: Amoxicillin - clavulanic acid for treating drug-resistant M tuberculosis. Chest (1991) 99:1025–1026.
   PubMed Web of Science ®Google Scholar
• WAYNE L, SRMEK H: Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimi-crob. Agents Chemother. (1994) 38:2054–2058.
   PubMed Web of Science ®Google Scholar
• ASHTEKAR D et al.: In vitro and in vivo activities of the nitroimidazole CGI 17341 against M tuberculosis. Anti-microb. Agents Chemother. (1993) 37:183–186.
   PubMed Web of Science ®Google Scholar
• MEINDL W, VON ANGERER E, SCHONENBERGER H, RUCKDESCHAL G: Benzylamines: synthesis and evalua-tion of antimycobacterial properties. J. Med. Chem. (1984) 27:1111–1118.
   PubMed Web of Science ®Google Scholar
• GRANGE J, SNELL N: Activity of bromhexine and am-broxol, semi-synthetic derivatives of vasicine from the Indian shrub Adhatoda Vasica, against M. tuberculo-sis in vitro. J. Ethnopharmacol (1996) 50:49–53.
   PubMed Web of Science ®Google Scholar
• BARBACHYN M et al.: Identification of a novel oxa-zolidinone (u-100480) with potent antimycobacterial activity. J. Med. Chem. (1996) 39:680–685.
   PubMed Web of Science ®Google Scholar
• ASHTEKAR D et al.: Oxazolidinones, a new class of syn-thetic antituberculosis agents. Diagn. Microbiol. Infect. Dis. (1991) 14:465–471.
   PubMed Web of Science ®Google Scholar
• OPRAVIL M et al.: Dapsone/pyrimethamine may pre-vent mycobacterial disease in immunosuppressed pa-tients infected with the human immunodeficiency virus. Clin. Infect. Dis. (1995) 20:244–249.
   PubMed Web of Science ®Google Scholar
• KANYOK T et al.: In vivo activity of paromomycin against susceptible and multidrug resistant M tuber-culosis and M. avium. Antimicrob. Agents Chemother. (1994) 38:170–173.
   PubMed Web of Science ®Google Scholar
• GANGADHARAM P: Gangamicin, a potential antimyco-bacterial drug. In: Programs and Abstracts of the 3311 ICAAC. New Orleans. Washington, USA American Society for Microbiology (1993). Abstract 73.
   Google Scholar
• JAGANNATH C, ALLAUDEEN H, HUNTER R: Activities of polaxamer CRL 8131 against M. tuberculosis in vitro and in vivo. Antimicrob. Agents Chemother. (1995) 39:1162–1165.
   PubMedGoogle Scholar
• HERZOG H: History of tuberculosis. Respiration (1998)65:5–15.
   PubMed Web of Science ®Google Scholar
• OTTENHAFF T, SPIERINGS E, NIBBERING P, DE JONG R: Modulation of protective and pathological immunity in mycobacterial infections. Int. Arch. Allergy Immunol (1997) 113:400–408.
   PubMed Web of Science ®Google Scholar
• ROOK G: Intractable mycobacterial infections associ-ated with genetic defects in the receptor for interferon-gamma: what does this tell us about immu-nity to mycobacteria? Thorax (1997) 52\(Suppl. 3):S41–S46.
   Google Scholar
• CONDOS R, ROM W, SCHLUGER N: Treatment of multi-drug resistant pulmonary tuberculosis with inter-feron-y via aerosol. Lancet (1997) 349:1513–1515.
   PubMed Web of Science ®Google Scholar
• GRANGE J: Immunotherapy: a new strategy for tuber-culosis control? Respir. Med. (1997) 91:1–4.
   Google Scholar
• ORME I: Progress in the development of new vaccines against tuberculosis. Int. J. Tuberc. Lung Dis. (1997) 1:95–100
   PubMed Web of Science ®Google Scholar
• BARRY C: New horizons in the treatment of tuberculo-sis. Biochem. Pharmacol (1997) 54:1165–1172.
   PubMed Web of Science ®Google Scholar
• ROM W, YIE T-A, TCHOU-WONG K-M: Development of a suicide gene as a novel approach to killing M. tubercu-losis. Am. J. Respir. Crit. Care Med. (1997) 156:1993–1998.
   PubMed Web of Science ®Google Scholar